Every 8-K that AI TECHNOLOGY GROUP INC (AIPG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AIPG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIPG filings page.
AI Technology Group Inc. amended its merger agreement with AVM Biotechnology and Biomed 360, updating investment tranches and extending the deal timeline. The parties confirmed $1,000,000 of Tranche 1 loans at $1.00 per share and $1,125,000 of Tranche 2 loans at $2.50 per share, both convertible into parent shares at the effective time. Additional Tranche 2 investments of $500,000 are scheduled on several monthly dates through October 15, 2026, plus $375,000 on November 15, 2026, all convertible at $2.50 per share with 10% simple annual interest. The amendment also targets Tranche 3 gross proceeds of at least $50,000,000 at $5.00 per share or higher in connection with a senior U.S. listing, and moves the closing date from July 26, 2026 to December 31, 2026, with possible further extension.
AI Technology Group Inc. filed an amendment describing its completed acquisition of AVM Biotechnology Inc. (AVMN). As a result of the amended share exchange agreement dated December 15, 2025, AVMN is now a wholly-owned subsidiary of the corporation.
As of December 15, 2025, AVMN had outstanding convertible debentures totaling $1,587,000, convertible into 634,800 common shares of AI Technology Group. These debentures will be converted into common shares under the share exchange agreement. Shares issued for the acquisition were unregistered, treated as restricted securities under Rule 144, and issued in reliance on the Section 4(a)(2) private offering exemption. The company will later file AVMN’s financial statements and related pro forma financial information by amendment within 71 days.
AI Technology Group Inc. filed an amendment describing revised funding terms and a new closing timeline for its transaction involving AVM Biotechnology. The parties confirmed that $1,000,000 of “Tranche 2” funding was provided on November 20, 2025, convertible into Parent Shares at $2.50 per share at the Effective Time.
Three additional $1,000,000 Tranche 2 increments are scheduled on or before February 28, 2026, April 30, 2026, and June 30, 2026, also convertible at $2.50 per share. A further “Tranche 3” investment between $10,000,000 and $25,000,000 is to be funded on or before the Closing Date and exchanged for Parent Shares at the same price. Tranche 2 and 3 amounts will accrue 10% per annum simple interest, settled in shares at $2.50 per share. The contractual Closing Date is extended from March 31, 2026 to July 26, 2026, unless the parties agree in writing to another date.
AI Technology Group Inc. reported that its board of directors and stockholders holding a majority of the voting power have approved a corporate name change to Biotechnology, Inc. by joint written consent dated January 22, 2026.
Before this name change takes effect, a Company–Related Action will be submitted to FINRA for review. The filing does not describe any changes to the company’s business operations or financial condition in connection with this action.
AI Technology Group Inc. updated the terms of its planned merger with Biomed 360 Solutions Corp. and related Nevada entity Biotechnology Inc. The amendment revises required investment tranches and extends the merger closing deadline.
The parties confirm a $1,000,000 loan labeled Tranche 1 was provided by August 1, 2025, convertible into parent shares at $1.00 per share at the effective time. They also confirm $1,000,000 of Tranche 2 was funded by November 20, 2025, convertible at $2.50 per share. Three additional Tranche 2 investments of $1,000,000 each are scheduled on or before February 28, 2026, April 30, 2026, and June 30, 2026, each convertible at $2.50 per share.
The amendment adds a Tranche 3 obligation for a minimum of $10,000,000 and up to $25,000,000 in loans on or before the closing date, also exchangeable into parent shares at $2.50 per share. Tranche 2 and Tranche 3 loans will accrue 10% per annum simple interest, to be settled in shares at $2.50 per share at the effective time. The merger closing date is extended from March 31, 2026 to July 26, 2026, unless another date is mutually agreed in writing.
AI Technology Group, Inc. reported that it and AVM Biotechnology, Inc. issued a joint press release about AI Technology Group’s funding efforts and AVM. The disclosure describes a proposed acquisition of AVM Biotechnology Inc. and anticipated financing transactions, including a private financing of at least $14 million at $2.50 per share or share equivalent, along with potential future tranches. It also outlines forward‑looking plans for AVM’s investigational product candidate AVM0703, including clinical development, regulatory interactions, manufacturing, and commercialization, while emphasizing significant risks and uncertainties that could affect whether the acquisition closes, capital is raised, and development and approvals progress as expected.
AI Technology Group Inc. reported that it has entered into and completed a share exchange to acquire 100% of AVM Biotechnology Inc. on December 15, 2025. The seller, Biomed 360 Solutions Corp., received 100 common shares of AI Technology Group, making AVM a wholly owned subsidiary in a stock-for-stock transaction intended to qualify as a tax-free reorganization under Section 368 of the Internal Revenue Code.
The filing notes that AVM has outstanding convertible debentures totaling $1,125,000, which are convertible into 584,800 common shares of AI Technology Group and will be converted into common shares under the agreement. The 100 shares issued in the acquisition were not registered under the Securities Act and are treated as restricted securities issued in reliance on Section 4(a)(2).